BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20235796)

  • 1. Pharmacogenomics in the treatment of inflammatory bowel disease.
    Smith MA; Marinaki AM; Sanderson JD
    Pharmacogenomics; 2010 Mar; 11(3):421-37. PubMed ID: 20235796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics and IBD: TPMT and thiopurines.
    Sandborn WJ
    Inflamm Bowel Dis; 2004 Feb; 10 Suppl 1():S35-7. PubMed ID: 15168829
    [No Abstract]   [Full Text] [Related]  

  • 4. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
    Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
    Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of inflammatory bowel disease.
    Kelleher D; Farrell R; McManus R
    Novartis Found Symp; 2004; 263():41-53; discussion 53-6, 211-8. PubMed ID: 15669633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic polymorphism and treatment of chronic bowel inflammatory diseases: the example of azathioprine].
    Bessard G; Hardy G; Chartier A; Stanke-Labesque F
    Therapie; 2004; 59(1):71-5. PubMed ID: 15199672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of inflammatory bowel disease.
    Katsanos KH; Papadakis KA
    Pharmacogenomics; 2014 Dec; 15(16):2049-62. PubMed ID: 25521361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
    De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of inflammatory bowel disease therapies.
    Sandborn WJ; Faubion WA
    Curr Gastroenterol Rep; 2000 Dec; 2(6):440-5. PubMed ID: 11079044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics in inflammatory bowel disease.
    Egan LJ; Derijks LJ; Hommes DW
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):21-8. PubMed ID: 16431300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of azathioprine products.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(4):219-23. PubMed ID: 14668694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
    Seidman EG
    Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine.
    Nguyen TM; Le Gall C; Lachaux A; Boulieu R
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):275-81. PubMed ID: 20353749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of thiopurines in inflammatory bowel disease.
    Derijks LJ; Wong DR
    Curr Pharm Des; 2010; 16(2):145-54. PubMed ID: 20205660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.